Dr Tsimberidou presents results at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting that show using molecular tests of tumours to select targeted therapy resulted in slower cancer growth and prolonged survival across a diverse set of cancer types.
She describes how, of the 1,307 patients with at least one genetic change in the cancer, the 3-year overall survival rate was 15% in the matched targeted group compared to 7% in the non-matched group.
The 10-year overall survival rate was 6% for the matched group and 1% in the non-matched group.
For more on these results, watch her interview with ecancer here, and read our news coverage here.
Slides from this presentation are available here.